Google
Trusted Resources: Community Center
Online groups, photo galleries and blogs
Sickle Cell Disease: Could Medical Cannabis and Crizanlizumab Prove Helpful?
Through a small academic setting survey, researchers at Yale University have discovered that sickle cell disease (SCD) patients are using marijuana to relieve symptoms related to the condition. How the substance is affecting these users and whether SCD should be added to the list of conditions that may be legally treated with medical cannabis is still in question. While medical marijuana in the US is legal to alleviate pain caused by several health conditions, only three states (Connecticut, Ohio, and Pennsylvania) include SCD as an approved condition. The Yale survey showed that SCD patients typically use marijuana as an alternative to opioids or supplement other pain relief treatments.
The survey included 58 SCD patients (age 21 and older), seen at an academic medical center, who were anonymously surveyed for their use of marijuana, cocaine, and phencyclidine (angel dust) for pain relief. Of the total study population, 42% reported using marijuana within the past two years; most patients said they used it for medicinal purposes to help with pain, anxiety, appetite, mood, and sleep. In addition, 79% of these patients reported taking less of their pain medications after marijuana use.
+myBinderRelated Content
-
A Conversation on Hydroxyurea: Insights and Information for the Sickle Cell Communityhttps://www.youtube.com/watch?v=Y6fmJn-5...
-
Eileen Hansbury, MSEileen Hansbury is a Physician Assistant...
-
Living Well With Sickle Cell Disease: Self-Care ToolkitWhat Is the Living Well With Sickle Cell...
-
2022 PCORI Annual MeetingThe PCORI Annual Meeting brings together...
-
Sarah Reeves, PhD, MPHDr. Reeves’ research is focused on imp...
-
Virginia Commonwealth University, Massey Cancer CenterVCU Massey Cancer Center is among the to...
-
Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in...Importance: In children with sickle cel...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
